AIDSACTION BALTIMORE, INC.

14 EAST EAGER STREET, BALTIMORE, MARYLAND 21202 (410) 837-2437 FAX (410) 837-2438 baltoaids@aol.com www.aidsactionbaltimore.org

ANNUAL REPORT 2021

AIDS Action Baltimore, Inc (AAB) is a non-profit, tax-exempt corporation under Section 501 (c)(3) of the Internal Revenue Code. AAB is governed by a seven member Board of Directors which is elected annually.

AIDS Action Baltimore, Inc. (AAB) is dedicated to providing patient services for all people in Baltimore City regardless of race, religion, age, disabilities, sexual orientation, gender or non-confirming gender, including emergency financial assistance, HIV education, HIV testing assistance, navigation support for healthcare linkage, retention in care, medication adherence and access support, HIV prevention services, including outreach efforts and pre-exposure prophylaxis (PrEP) medication access.

AIDS Action Baltimore (AAB) has been providing essential services to people with HIV/AIDS since 1987. AAB provides all these services with four full-time employees, and our committed volunteers. AAB's administrative expenses for 2021 totaled only 4.3% of total revenues. (www.aidsactionbaltimore.org)

Although HIV disease is becoming a chronic manageable disease, AAB still provides financial assistance to many needy people with HIV/AIDS. AAB has provided this support to over 8,750 people since 1987 and \$3,145,000 in assistance for items such as rent and utilities, and direct programs in our community to people with HIV/AIDS and their families. We firmly believe we must continue our invaluable financial assistance program which provides a safety net to people with HIV/AIDS experiencing an emergency financial crisis.

In the latest Centers for Disease Control (CDC) data reported in 2020, Maryland was ranked 8th among U.S. states and territories in adult/adolescent HIV diagnosis rates (per 100,000) in 2019. At the end of 2020, there were 31,676 people aged 13 and older living with diagnosed HIV in Maryland. An estimated 3,559 people with HIV (PWHIV) in Maryland in 2019 remain undiagnosed.

AAB has been instrumental again this year in reducing HIV transmission in Baltimore. By race, the lifetime risk of HIV is one in 22 for Black males, one in 51 for Latinx males, and one in 140 for White males. We are currently administering an HIV PrEP prevention program, known as New Horizons. PrEP is a one pill, once a day pill that has proven to be 99% effective in reducing HIV transmission risk. Our HIV prevention program provides outreach, education, testing assistance, healthcare linkages, navigation support and support groups that promote medication adherence for African-American Transgender (Trans) people and Gay men at risk of HIV and also for people who are HIV positive. We also provide our clients with the latest in HIV prevention and treatment research information.

New Horizons promotes a continuum of care HIV prevention and/or HIV treatment including retention in care and adherence to life-saving medications in Gay men and Trans people as well. Our prevention and treatment efforts have been extremely successful. We seek to educate Black Gay men and Trans people about their exorbitant risk of HIV transmission, and help them build networks of support to combat the many social obstacles

they encounter daily which contribute to their risk of HIV, causing them to fall in and out of care and treatment. We have also been educating people about Treatment as Prevention (TASP), also known as U=U (Undetectable HIV = Untransmittable HIV). If a person's HIV viral load is undetectable, they can not transmit HIV to another person! We are very proud of our very successful support and education programs which have helped to decrease HIV as well as the number of PWHIV we have helped to access and remain on life-saving HIV medications. AAB can continue to these life-saving programs with your help.

Our national work affects all who are touched by HIV/AIDS. We are working with industry to continually change the standard of care by ensuring that their new drug pipelines remain robust, and by replacing older more toxic drugs with more effective, better tolerated drugs, as well as exciting new long-acting drugs for HIV prevention and treatment that may require only daily, weekly or monthly dosing. This is the wave of the future.

AAB has been instrumental in the formation of the Drug Development Committee of the AIDS Treatment Activists Coalition, a national organization that interacts with the pharmaceutical industry, pressuring companies to study drugs expeditiously and ethically and to include the HIV affected community in all aspects of research and development. AAB has also been a leading member of the national Fair Pricing Coalition (FPC), pressuring "big pharma" to price HIV drugs reasonably, limit price increases, cap ongoing drug prices for government programs like AIDS Drug Assistance Programs, and to initiate co-pay programs for patients with private insurance. We convinced every HIV and Hepatitis C drug company to create programs that will cover outrageously expensive co-pays and other out of pocket (OOP) costs for people with private insurance. Our work directly affects Marylanders with ever increasing OOP prescription costs. We are also working very hard to ensure that people in Maryland and across the country who cannot afford their medications get their drugs for free from "big pharma" through Patient Assistance Programs (PAPs). These OOP co-pay programs are now in danger of being discontinued by insurance providers. AAB has been trying to work in collaboration with numerous national organizations to preserve co-pay programs which have recently come under attack by healthcare insurance companies. We are also currently leading a coalition of local service providers to make sure the Maryland AIDS Drug Assistance Program begins to function properly after the hack of Maryland Department of Health's computers. With the help of this coalition and your continued support, we will be able to ensure that PWHIV receive their HIV medications without further interruptions.

We are very excited that scientists have begun to work on HIV "cure- related" research. AAB is working with government, industry and the national HIV community nationally to make a "cure" for HIV or what we are now calling "durable HIV suppression" a reality. Even though this will take years to come to fruition, we have to start somewhere. AAB is a member of the DARE Martin Delaney Cure Research Collaboratories. AAB is also working with DARE researchers to bring additional resources to Baltimore for local cure research projects. We conducted four HIV Cure Forums in 2019 to 2022.

HIV policy gets more complicated every year. COVID-19 is eating a large percentage of US Health and Human Services (HHS) funding. We are in danger of losing all our hard won treatment and prevention gains. Because of COVID-19, it is much harder to obtain the money we need to fight HIV. We are working very closely with the Baltimore City Health Department (BCHD) in their End the HIV Epidemic Initiative. The BCHD has also provided funding for our prevention and treatment programs. We had nine Town Halls in conjunction with the BCHD from 2020 to 2022, discussing new HIV and COVID-19 news. Innovative events like this would not happen without AIDS Action Baltimore.

AAB successfully advocated for increased NIH HIV research funding, and will continue to advocate for other HHS budget increases, like continued funding for the Ryan White Care Act for the support of people with HIV. We have also been working diligently on COVID-19 advocacy and support. We are using our many years of government research and policy expertise and connections in the fight against COVID-19. AAB was instrumental in ensuring that PWHIV were not excluded from COVID-19 vaccine protocols, and worked

tirelessly to ensure that PWHIV were finally prioritized for COVID-19 vaccinations both nationally and in Maryland. We spearheaded many months of high level advocacy, collaborating with national activists to ensure that PWHIV were included in COVID-19 vaccine trials and prioritized for vaccines.

AAB filed written public comments for every FDA COVID-19 vaccine authorization hearing and was chosen to make oral comments at many FDA hearings. We also filed public comments for many CDC COVID-19 vaccines hearings. We will continue to advocate with the NIH to assure that clinical trials for people with COVID-19 are conducted ethically and expeditiously, and to ensure that PWHIV are included in important clinical trials. Advocating for such life-saving strategies has been our life's work. Our expertise and long-standing contacts in these arenas are invaluable. Our work is way ahead of the curve. The type of advocacy AAB does not happen in any other disease community.

AAB helped to fund local COVID-19 food insecurity efforts for people with HIV, and expanded our financial assistance programs for PWHIV who have COVID-19 emergencies. During the initial shut-down, we sent needy clients COVID-19 care packages that included masks, hand sanitizer and important COVID-19 information.

Our city and country need the expertise of AIDS activists now more than ever. As always, we will continue to work locally and nationally for PWHIV and now for PWHIV and COVID-19.

Contributing Organizations: AIDS Healthcare Foundation, Baltimore City Health Department, Broadway Cares/Equity Fights AIDS, Brother Help Thyself, CareFirst, Gilead, Johnson & Johnson Healthcare Systems, MD DHCD Non-Profit Recovery Initiative, MD Department of Health, Network for Good, Nordstrom and the M-A-C AIDS Fund, Open Society, 12 Days of Christmas and ViiV.

BOARD OF DIRECTORS

Merle McCann, M.D. - Chairman 336 Market Street Lewes, DE 19958

Michael Aquino 41340 Gloucester Drive Rehobeth, MD 19971

Jake Boone 235 West Lafayette Baltimore, MD 21217

Non-Voting Members

Lynda Dee, J.D. - Executive Director 3928 Cloverhill Road Baltimore, MD 21218 Thomas Holden 3626 Yolando Road Baltimore, MD 21218

Mark McMullen 3505 Newland Road Baltimore, MD 21218

Cameron Wolf, Ph.D. 8706 Granite Lane Laurel, MD 20708

2021 EVENTS

January

Nominations for Board of Directors

IAS HIVR4P//Virtual Conference

Brother Help Thyself Grant Award Ceremony

T.E.A. Time and New Horizons Meetings

February

Election of Board of Directors

Combined Charity Campaigns Acceptance

National Black HÍV/AIDS Awareness Day

March

MD State Combined Charity Campaign Acceptance

28th Conference on Retroviruses & Opportunistic Infections (CROI)

CROI 2021and Maryland COVID-19 Update Town Hall

April

National CFAR Ending the HIV Epidemic Meeting

National Transgender HIV Testing Day and Health Awareness Week

T.E.A. Time, PrEP UP and New Horizons Meetings

May

Direct Mail Drive

Ride for Moveable Feast

T.E.A. Time and New Horizons Meetings

June

Gay Pride Celebration

National HIV Testing Day

T.E.A. Time and New Horizons Meetings

CROI 2021 and Maryland Update Town Hall

July

24th International AIDS Conference

World Hepatitis Day

T.E.A. Time and New Horizons Meetings

August

BCHD EHE Grant Award

Baltimore Trans Pride

T.E.A. Time, PrEP UP and New Horizons Meetings

September

Clifton Mansion Benefit

Dining Out for Life

T.E.A. Time and New Horizons Meetings

October

Baltimore Black Pride Celebration

T.E.A. Time and New Horizons Meetings

COVID-19 Booster Vaccines Town Hall

November

Transgender Day of Remembrance

ViiV Healthcare 23rdh Annual Community Summit

Direct Mail Campaign

T.E.A. Time and New Horizons Meetings

Transgender Remembrance Day Town Hall

December

World AIDS Day Celebration of Life

Martin Delaney Collaboratories for HIV Research

Christmas Outreach

INDEPENDENT AUDITOR'S REPORT

To The Board of Directors, AIDS Action Baltimore, Inc.

Opinion

We have audited the accompanying financial statements of AIDS Action Baltimore, Inc. (a nonprofit organization) which comprise the statement of financial position as of December 31, 2021 and 2020, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of AIDS Action Baltimore, Inc. as of December 31, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further descripted in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of AIDS Action Baltimore, Inc. and to meet of other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair representation of these financial statements in accordance with accounting principles generally accepted in the United States of America; and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about AIDS Action Baltimore, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that included our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always deduct a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is substantial likelihood that, individually or in the aggregate, that would influence the judgement made by a reasonable used based on the financial statement.

In performing an audit in accordance with generally accepted auditing standards, we:

• Exercise professional judgement and maintain professional skepticism throughout the audit.

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures including examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit on order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of AIDS Action Baltimore, Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about AIDS Action Baltimore, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Friedman and Associates, P.A., Certified Public Accountants and Business Advisors Baltimore, Maryland June 9, 2022

The following financial information is excerpted from the Auditor's Report. A complete copy of the Auditor's Report and Accompanying Notes, and/or current financial statement is available upon request by contacting AIDS Action Baltimore, Inc. at 14 East Eager Street, 1-A Baltimore, MD 21202 or 410-837-2437. Documents and information submitted to the State of Maryland under the Maryland Charitable Solicitations Act are available from the Office of the Secretary of State, State House, Annapolis, MD 21401 for the cost of copying and postage.

AIDS ACTION BALTIMORE, INC. Statement of Financial Position as at December 31, 2021 and 2020

ASSETS		
Current Assets	2021	2020
Cash and Cash Equivalents	\$ 258,985	\$ 224,426
Contributions Receivable	41,983	53,693
Prepaid Expenses	769	769
TOTAL CURRENT ASSETS	\$ 301,737	\$ 278,888
Furniture & Equipment		
Furniture and Equipment	\$ 64,124	\$ 63,126
Less: Accumulated Depreciation	60,990	59,235
TOTAL FURNITURE & EQUIPMENT	3,133	3,891
OTHER ASSETS		
Security Deposit	\$ 1,000	1,000
TOTAL OTHER ASSETS	\$ 1,000	1,000
TOTAL ASSETS	\$ <u>305,870</u>	\$ <u>283,779</u>
LIABILITIES & NET ASSETS		
CURRENT LIABILITIES		
Accrued Expense Payable	\$ 3,221	\$ 3,661
Credit Card Payable	-0-	1,563
Payroll Taxes Payable	<u>-0-</u>	<u>-0-</u>
TOTAL CURRENT LIABILITIES	\$ 3,221	\$ 5,224
NET ASSETS		
Unrestricted	\$ 291,332	\$ 260,706
Temporarily Restricted	<u>11,317</u>	<u>17,849</u>
TOTAL NET ASSETS	\$ 302,649	\$ 278,555
TOTAL LIABILITIES & NET ASSETS	\$ 305,870	\$ 283,779

AIDS ACTION BALTIMORE, INC.

Statement of Activities

For The Years Ended December 31, 2021 and 2020

For the fears Ended December 31, 2021 and 2020					
	Temporarily	Un-	2021	2020	
	Restricted	Restricted	Total	Total	
PUBLIC SUPPORT		<u></u>	<u> </u>	<u> </u>	
AND REVENUE					
PUBLIC SUPPORT:					
Contributions	\$ 15,000	\$ 24,831	\$ 39,831	\$ 56,629	
Special Events	-0-	35,738	35,738	18,407	
Grants-Education	<u>-0-</u>	276,071	276,071	210,756	
Total Public Support	\$ 15,0 00	\$ 336,640	\$ 351,640	\$ 285,792	
Net Assets Released					
from Restriction	-0-	-0-	-0-	-0-	
REVENUE:					
Rental Income	-0-	-0-	-0-	-0-	
Investment Income	-0- -0-	18	18	45	
TOTAL SUPPORT					
AND REVENUE	\$ 15,000	\$ 336,658	\$ 351,658	\$ 285,837	
MINDINEVERIOR	Ψ 10,000	φ 000,000	φ σσ 1,σσσ	Ψ 200,007	
EXPENSES					
Program Services:	24 472	200 075	210 047	227.004	
Public Services	21,172	288,875	310,047	327,994	
SUPPORTING SERVICES		47.547	47.547	00.004	
Management and General		17,517	17,517	20,021	
TOTAL EXPENSES	\$ 21,172	$\$ \overline{306,392}$	\$ 327,564	\$ 348,015	
Change in Net Assets	(6,172)	30,266	24,094	(62,178)	
NET ASSETS -					
BEGINNING OF THE YEA	AR 17,489	261,287	278,555	340,733	
NET ASSETS -					
END OF THE YEAR	\$ <u>11,317</u>	\$ <u>291,553</u>	\$ <u>302,649</u>	\$ <u>278,555</u>	
	Ψ <u>· · · · · · · · · · · · · · · · · · ·</u>	ψ <u>=υ:,υυυ</u>	+ 002,010	+ <u>=: 0,000</u>	